Windtree Therapeutics, Inc. (NASDAQ:WINT) Files An 8-K Other Events
Item 8.01.
|
Other Events. |
On June 1, 2017, Windtree Therapeutics, Inc. (the Company) issued
a press release announcing the completion of enrollment in the
Companys AEROSURF phase 2b clinical trial evaluating aerosolized
KL4 surfactant for the treatment of respiratory distress syndrome
(RDS) in premature infants, 28 to 32 week gestational age,
receiving nasal continuous positive airway pressure (nCPAP) for
RDS, a copy of which is attached as Exhibit 99.1 to this Current
Report on Form 8-K. In addition, the Company reaffirms its plan
to announce top-line results for the trial in July 2017.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
|
|
99.1 |
Press release dated June 1, 2017 |
Cautionary Note Regarding Forward-looking
Statements:
To the extent that statements in this Current Report on Form 8-K
are not strictly historical, including statements as to business
strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Companys product
development, cash flows, future revenues, the timing of planned
clinical trials or otherwise as to future events, such statements
are forward-looking, and are made to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this Current Report are
subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
Such risks and others are further described in the Companys
filings with the Securities and Exchange Commission including the
most recent reports on Forms 10-K, 10-Q and 8-K, and any
amendments thereto. Any forward-looking statement made by the
Company in this Current Report on Form 8-K is based only on
information currently available to the Company and speaks only as
of the date on which it is made. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
About Windtree Therapeutics, Inc. (NASDAQ:WINT)
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death. Windtree Therapeutics, Inc. (NASDAQ:WINT) Recent Trading Information
Windtree Therapeutics, Inc. (NASDAQ:WINT) closed its last trading session down -0.010 at 0.960 with 1,244,603 shares trading hands.